Clinical trials: Hypertension, Pulmonary Artery
Pulmonary Arterial Hypertension
Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension
This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected to include 60…
- Trial name
- NCT04483115
- Testing
- TPN171H, Tadalafil
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- Vigonvita Life Sciences
Pulmonary Arterial Hypertension
Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
To evaluate the effect of inhaled treprostinil compared to placebo on exercise capacity and time to clinical worsening.
- Trial name
- INTREPID (NCT01557647)
- Testing
- Inhaled treprostinil
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension
Pulmonary hypertension is a rare condition that leads to right ventricular dysfunction and premature death. Only modest improvements of outcomes have been observed with the current available advanced specific drug therapy.
- Trial name
- DENERV'AP (NCT02525926)
- Testing
- denervation
- Where
- 5 sites in France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Pulmonary Hypertension
Hydroxyurea in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a serious and eventually fatal disease damaging the lungs and the heart. It results from narrowing and eventual blockage of small blood vessels in the lung, due to abnormal proliferation…
- Trial name
- NCT01950585
- Testing
- Hydroxyurea
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Artery Hypertension
Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)
The objective of this project is to determine how pulmonary vascular remodeling in Pulmonary Arterial Hypertension (PAH) at cellular and pathological level is associated with gas exchange physiology changes and hemodynamics…
- Trial name
- NCT06122922
- Testing
- Hyperpolarized Xe129
- Sponsor
- Bastiaan Driehuys
Pulmonary Arterial Hypertension
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension
This is a prospective pilot study to assess the plasma levels of particular proteins involved in the transforming growth factor beta (TGF-β) pathway and its down stream regulators, CHIP, as well as micro RNA molecules in subjects…
- Trial name
- NCT04489251
- Testing
- Protein Elisa analysis, microRNA analysis, whole exome sequencing
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical College of Wisconsin
Pulmonary Arterial Hypertension
FreeFlow Percutaneous Atrial Septal Shunt for IPAH
The goal of this clinical trial is to explore the safety and efficacy of the FreeFlow percutaneous atrial septal shunt for treatment of idiopathic pulmonary arterial hypertension.
- Trial name
- FREEFLOW (NCT06605794)
- Testing
- FreeFlow percutaneous atrial septal shunt
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Pulmonary Hypertension
Colchicine in Pulmonary Artery Hypertension Patients
This study evaluates the efficacy of colchicine in improving cardiopulmonary function for patients diagnosed with Pulmonary Arterial Hypertension (PAH), a condition characterized by elevated pulmonary pressure that impairs right…
- Trial name
- NCT07907757
- Testing
- Colchicine 0.5 MG Oral Tablet
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Chronic Lung Diseases
The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary…
- Conditions
- Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07777367
- Testing
- 6-minute walk distance (6MWD) test on ambient conditions, 6-minute walk distance (6MWD) test with supplemental oxygen (LOX)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension
FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
Mutations in bone morphogenetic protein receptor 2 (BMPR2) are present in >80% of familial and ~20% of sporadic pulmonary arterial hypertension (PAH) patients.
- Trial name
- TransformPAH (NCT01647945)
- Testing
- FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Edda Spiekerkoetter
Pulmonary Arterial Hypertension, Congenital Heart Disease
Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease
Pulmonary arterial hypertension (PAH), or high blood pressure in the lungs, is common in patients with congenital heart disease.
- Conditions
- Pulmonary Arterial Hypertension, Congenital Heart Disease, Eisenmenger's Syndrome
- Trial name
- NCT01319045
- Testing
- Iloprost
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, Los Angeles
Pulmonary Arterial Hypertension
The Expression and Significance of MiRNA
It is not always known what causes PAH or what the best treatment is. The doctors doing this study would like to understand more about why some people develop PAH and other do not.
- Trial name
- NCT00806312
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Megan Ballinger
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with…
- Trial name
- PAH (NCT01457781)
- Testing
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
- Where
- 51 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Hypertension
Right Ventricular and Pulmonary Artery Evaluation by CMR
Pulmonary hypertension results in right ventricle dysfunction. Cardiac magnetic resonance derived RV ejection fraction is a prognostic value in this condition.
- Trial name
- NCT03377673
- Testing
- CMR
- Where
- Lithuania
- Volunteers
- 100 people
- Sponsor
- Lithuanian University of Health Sciences
Pulmonary Arterial Hypertension
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07441200
- Testing
- NS-863 Low Dose, NS-863 High Dose
- Where
- Japan
- Volunteers
- 135 people
- Sponsor
- NS Pharma, Inc.
Pulmonary Arterial Hypertension
DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study
The purpose of the DelIVery for PAH clinical study is to evaluate the safety of the Medtronic Model 10642 Implantable Intravascular Catheter when used with the Medtronic SynchroMed® II Implantable Infusion System to deliver…
- Trial name
- DelIVery (NCT01321073)
- Testing
- Model 10642 Implantable Intravascular Catheter
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)
Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension
Hypothesis: The small molecule and metabolic modulator Dichloroacetate (DCA) is safe, tolerated as a potential therapy in patients with moderate or severe Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT01083524
- Testing
- Dichloroacetate Sodium
- Where
- 2 sites in Canada, United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Alberta
Pulmonary Arterial Hypertension
Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058
the purpose of this study is to determine the effect of age on the Pharmacokinetics (PK) profile of BIA 5-1058 at steady state after multiple oral doses
- Trial name
- NCT04991194
- Testing
- BIA 5-1058
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Impact of Rehabilitation Program on PAH Patients Treated With Macitentan.
48 patients, over the age of 18, with pulmonary arterial hypertension (PAH) classified as WHO III-IV, that are all stable under Macitentan therapy ( medication for treating PAH patients), will be recruited to the study through…
- Trial name
- NCT03045666
- Testing
- Exercise program
- Volunteers
- 48 people
- Sponsor
- Soroka University Medical Center